Meghan Samberg

Meghan Samberg, PhD, is experienced in growing seed stage companies within the fields of regenerative and translational medicine with specialties in skin wound healing, tissue engineering, animal model development and testing, nanoparticle toxicology, biomaterial fabrication, and lyophilization. Prior to joining Stemson, Meghan simultaneously served as the VP of Clinical Affairs at ISTO Biologics, an orthobiologics company, where she led all laboratory, preclinical, and clinical research efforts, and VP & GM of Compass Biomedical, a biologics company specializing in blood-based products and therapies. In addition to serving as the PI and PM on multi-million-dollar NIH, DoD, and BARDA funded preclinical and clinical programs for Compass products, she oversaw the CDMO services for seed stage companies, translating their R&D concepts into cGMP processes and serving as their regulatory contact. Meghan holds a BS in Biological Engineering from the University of Georgia, an MS in Biomedical Engineering from Yale University, and a PhD from The University of North Carolina at Chapel Hill and North Carolina State University. She conducted post-doctoral research at NCSU and at the United States Army Institute for Surgical Research at Fort Sam Houston.